Search Results for: Clinical Roundup
-
Pharma: Clinic Roundup
Inc., of Whitehouse Station, N.J., said researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of Tredaptive (extended-release niacin/laropiprant) during the late-breaking clinical trial session at the American College of Cardiology 62nd Annual Scientific Session in San Francisco...Findings were presented during the late-breaking clinical trial sessionBioWorld Today | Tuesday, March 12, 2013 -
Pharma: Clinic Roundup
Janssen and partner Bayer AG, of Leverkusen, Germany, will enroll patients into five global clinical trials, which will involve a total of 28,850 patientsBioWorld Today | Monday, March 11, 2013 -
Clinic Roundup
Zealand Pharma A/S, of Copenhagen, Denmark, disclosed in a pipeline update that it plans to advance danegaptide into a single site clinical efficacy study to further profile the peptide drug in cardio protectionBioWorld Today | Monday, March 11, 2013 -
Following Ravicti Win in UCD, Hyperion Seeks $59.7M for HE
The company plans to use proceeds from the offering to complete clinical development of Ravicti in hepatic encephalopathy (HE) and to fund post-approval studies in UCD...at the same unit price.By Marie Powers | BioWorld Today | Monday, March 11, 2013 -
AAD Roundup
The ATX-101 global clinical development program has enrolled more than 2,500 total patients, of which more than 1,500 have been treated with ATX-101, the company saidBioWorld Today | Tuesday, March 5, 2013 -
Clinic Roundup
Vertex Pharmaceuticals Inc., of Cambridge, Mass., said VX-787 in a Phase II influenza challenge study resulted in statistically significant improvements in viral and clinical measurements of infection...Also, 93 percent of people in that dose group showed no clinical symptoms of influenza after three days of treatment, compared to 41 percent of people in the placebo groupBioWorld Today | Tuesday, March 5, 2013 -
Pharma: Clinic Roundup
Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, reported the first interim results in HCV/HIV co-infected patients from the company's ongoing hepatitis C (HCV) clinical trial program, HCVerso...Polyphor Ltd., of Allschwil, Switzerland, completed a Phase I trial demonstrating the clinical safety and tolerability of its Pseudomonas-specific antibiotic POL7080...The study compared the efficacy and safety of once-weekly Milprosa to daily 8 percentBioWorld Today | Tuesday, March 5, 2013 -
Ablynx Pads Cash Reserves to Push RA Drug into Phase IIb
In total, Ablynx has five products in clinical development and six in preclinical development, of which five are with partners...At the completion of the capital raising, Bionomics will have approximately $26 million in cash.By Nuala Moran | BioWorld Today | Tuesday, March 5, 2013 -
Financings Roundup
Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets...It also will support preparatory work to advance the firm's clinical-stage oncology program, DPX-Survivac, into Phase II development...It will use the proceeds to advance its opthalmic programs through clinical proof of conceptBioWorld Today | Friday, March 1, 2013 -
Pharma: Clinic Roundup
The volasertib clinical development program is the company's most advanced in cell cycle inhibitionBioWorld Today | Friday, March 1, 2013 -
Financings Roundup
Proceeds will be used to support continuing clinical development of Ravicti (glycerol phenylbutyrate) in HE, a brain disorder caused by chronic liver failureBioWorld Today | Thursday, February 28, 2013 -
Clinic Roundup
In conjunction with the changes in its clinical program, the company said it reduced its work force by 50 percent and outsourced noncritical research and development functionsBioWorld Today | Wednesday, February 27, 2013 -
$7M Series B Puts Investor Skin in Game for Brickell
The company is planning to begin clinical studies in the first half of 2014...The product, a therapeutic antibody, has shown potential in preclinical studies to to reduce damage, allowing pumping efficiency to return to normal levels.By Catherine Shaffer | BioWorld Today | Wednesday, February 27, 2013 -
Clinic Roundup
The study also has exploratory endpoints for clinical efficacy and inflammation biomarkers...Ltd., of Taipei, Taiwan, added two additional Taiwanese clinical centers in Cel-Sci's Phase III head and neck cancer trial for Multikine (Leukocyte Interleukin, Injection), including the China Medical University Hospital, of Taichung, Taiwan, and the Buddhist Tzu Chi General Hospital, of Hualian, TaiwanBioWorld Today | Tuesday, February 26, 2013 -
White House: Give the Public its Money's Worth
The agency also finalized its draft guidance on financial disclosures by clinical investigators...and explains the FDA's review of clinical investigator financial disclosure information.By Mari Serebrov | BioWorld Today | Tuesday, February 26, 2013 -
Pharma: Clinic Roundup
Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said pinoxacin hydrochloride received approval for clinical studies from the State Food and Drug AdministrationBioWorld Today | Monday, February 25, 2013 -
Immunomedics Seeks $14M as Bridge to Milestones
UCB also picked up clinical development and commercialization costs. (See BioWorld Today, May 11, 2006.) In 2009, the companies reported results from a Phase IIb dosing study of the drug showing a 24.9 percent treatment advantage over placebo in systemic lupus erythematosus (SLE) patients...The funding will support the advancement of Blaze's Tumor Paint product candidate, BLZ-100, into clinical development for use in surgery in multiple solid tumor types. (See BioWorld Today, June 11, 2012...OxygenBy Marie Powers | BioWorld Today | Monday, February 25, 2013 -
Clinic Roundup
The clinical trial is a randomized, double-blind, placebo-controlled parallel group study to evaluate the safety, clinical efficacy and pharmacokinetic profile of bertilimumab in subjects with active moderate-to-severe ulcerative colitis...Repros Therapeutics Inc., of The Woodlands, Texas, provided a clinical update of its Androxal Phase III program following receipt of written guidance from the FDABioWorld Today | Friday, February 22, 2013 -
Oncolytics Stock Offering Gets $32M to Push Reolysin
NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, is conducting four studies in various tumor types, which will "go a long way to helping us figure out" where to put the most resources, Look said...The multitude of clinical trials adds up to a program that "sounds like a heck of a burn requirement...The initial fundings position Cytomedix to execute on its 2013 operational business plan, the company said.By Randy Osborne | BioWorld Today | Thursday, February 21, 2013 -
Clinic Roundup
The primary objectives include the evaluation of adverse events and the evaluation of six-month clinical response...Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase II study, titled "Double-Blind, Placebo-Controlled Clinical Trial of EPI-743 in Patients with Cobalamin C DefectBioWorld Today | Wednesday, February 20, 2013
Category
Current Filters
- xNOT BioWorld International
Related Keywords
Categories
- x BioWorld Today (2583)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.